1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Poulsen, S.-A.
Watson, A.A.
Craik, D.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Struct.Biol.
JSBIEM
0803
1047-8477
130
142
152
10.1006/jsbi.2000.4267
10940222
Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F)
2000
10.2210/pdb1bjb/pdb
pdb_00001bjb
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
3268.439
AMYLOID BETA-PEPTIDE
ABETA [F16], RESIDUES 1-28
K16E
1
man
polymer
no
no
DAEFRHDSGYEVHHQELVFFAEDVGSNK
DAEFRHDSGYEVHHQELVFFAEDVGSNK
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
32644
unidentified
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1998-11-04
1
1
2008-03-24
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
_struct_ref_seq_dif.details
Y
BNL
1998-06-23
REL
REL
THE STRUCTURE WAS DETERMINED FROM 2-DIMENSIONAL NMR DATA ON UNLABELLED PEPTIDE
LOW ENERGY, LOW VIOLATIONS
50
14
NOESY
TOCSY
5.6
1
atm
296
K
REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE
SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS
SDS MICELLES (100MM)/D2O, H2O
BRUNGER
refinement
XPLOR
structure solution
X-PLOR
500
Bruker
AMX-500
750
Bruker
DRX-750
ASP
1
n
1
ASP
1
A
ALA
2
n
2
ALA
2
A
GLU
3
n
3
GLU
3
A
PHE
4
n
4
PHE
4
A
ARG
5
n
5
ARG
5
A
HIS
6
n
6
HIS
6
A
ASP
7
n
7
ASP
7
A
SER
8
n
8
SER
8
A
GLY
9
n
9
GLY
9
A
TYR
10
n
10
TYR
10
A
GLU
11
n
11
GLU
11
A
VAL
12
n
12
VAL
12
A
HIS
13
n
13
HIS
13
A
HIS
14
n
14
HIS
14
A
GLN
15
n
15
GLN
15
A
GLU
16
n
16
GLU
16
A
LEU
17
n
17
LEU
17
A
VAL
18
n
18
VAL
18
A
PHE
19
n
19
PHE
19
A
PHE
20
n
20
PHE
20
A
ALA
21
n
21
ALA
21
A
GLU
22
n
22
GLU
22
A
ASP
23
n
23
ASP
23
A
VAL
24
n
24
VAL
24
A
GLY
25
n
25
GLY
25
A
SER
26
n
26
SER
26
A
ASN
27
n
27
ASN
27
A
LYS
28
n
28
LYS
28
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
5
-3.04
0.50
120.30
117.26
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
5
5
5
N
7
-4.29
0.70
120.80
116.51
A
A
A
CB
CG
CD2
PHE
PHE
PHE
19
19
19
N
13
-4.51
0.70
120.80
116.29
A
A
A
CB
CG
CD2
PHE
PHE
PHE
19
19
19
N
1
A
ALA
2
-86.36
-82.11
1
A
GLU
3
-162.97
91.97
1
A
PHE
4
-173.87
-15.68
1
A
ARG
5
-141.01
45.83
1
A
HIS
6
-150.66
-48.54
1
A
ASP
7
-150.13
32.25
1
A
SER
8
-167.31
41.25
1
A
TYR
10
36.29
-146.32
1
A
GLU
11
-164.26
7.81
1
A
VAL
12
69.61
-42.48
1
A
HIS
13
75.48
40.17
1
A
SER
26
-170.11
36.47
2
A
ALA
2
-82.79
-95.09
2
A
GLU
3
-156.34
83.44
2
A
PHE
4
-147.95
-62.91
2
A
ASP
7
-165.86
35.20
2
A
SER
8
-162.37
36.88
2
A
HIS
13
76.23
-2.50
3
A
GLU
3
-177.67
7.03
3
A
ASP
7
-174.39
15.59
3
A
SER
8
-147.04
32.99
3
A
GLU
11
-172.44
141.72
3
A
VAL
12
-143.01
-59.75
3
A
HIS
13
65.31
-2.13
3
A
HIS
14
-89.60
-97.76
3
A
SER
26
-167.77
47.91
4
A
ALA
2
-165.74
-62.41
4
A
GLU
3
-160.86
7.23
4
A
HIS
6
-137.99
-54.32
4
A
TYR
10
-59.32
175.24
4
A
VAL
12
-138.03
-54.21
4
A
HIS
13
78.76
-5.08
4
A
HIS
14
-98.26
-98.65
4
A
SER
26
-147.84
46.80
5
A
PHE
4
-158.26
-26.92
5
A
TYR
10
-64.41
-168.71
5
A
HIS
13
58.29
7.07
5
A
HIS
14
-87.70
-76.19
5
A
SER
26
42.52
27.67
5
A
ASN
27
-151.25
-70.12
6
A
ALA
2
-71.99
-73.36
6
A
GLU
3
-172.49
21.32
6
A
ASP
7
-176.33
25.80
6
A
SER
8
-161.59
45.68
6
A
GLU
11
-158.29
21.25
6
A
VAL
12
72.49
-34.66
6
A
HIS
13
74.86
38.07
6
A
HIS
14
-137.56
-79.54
6
A
SER
26
-149.07
-84.10
7
A
GLU
3
48.04
18.84
7
A
SER
8
-176.68
34.40
7
A
GLU
11
39.11
106.67
7
A
VAL
12
-126.93
-63.77
7
A
HIS
13
82.11
7.66
7
A
HIS
14
-104.68
-78.16
8
A
GLU
3
32.73
32.31
8
A
HIS
6
52.88
17.08
8
A
ASP
7
127.98
37.67
8
A
VAL
12
-153.86
-60.84
8
A
HIS
13
74.87
-18.28
8
A
ASN
27
72.61
56.12
9
A
GLU
3
63.92
101.91
9
A
PHE
4
-163.89
-38.92
9
A
ASP
7
-141.09
19.92
9
A
TYR
10
-60.17
-179.78
9
A
VAL
12
-143.55
-54.46
9
A
HIS
14
-119.30
-94.07
10
A
GLU
3
36.19
32.29
10
A
PHE
4
-75.96
24.91
10
A
SER
8
62.53
64.82
10
A
VAL
12
-129.14
-60.69
10
A
HIS
14
-93.81
-88.95
10
A
SER
26
-75.63
-93.96
11
A
GLU
3
54.81
18.09
11
A
ARG
5
-65.47
10.07
11
A
ASP
7
-152.19
19.11
11
A
VAL
12
-131.33
-62.23
11
A
HIS
13
77.30
-22.72
11
A
HIS
14
-75.17
-95.90
11
A
SER
26
47.09
27.74
12
A
ALA
2
-154.49
-107.85
12
A
GLU
3
-168.75
27.27
12
A
ASP
7
-165.08
35.82
12
A
SER
8
-158.56
32.17
12
A
VAL
12
-139.16
-50.59
12
A
HIS
13
73.73
-7.35
12
A
HIS
14
-95.46
-97.63
12
A
SER
26
42.09
22.83
13
A
GLU
3
38.76
31.61
13
A
ARG
5
91.60
56.89
13
A
ASP
7
76.68
38.02
13
A
SER
8
64.63
75.73
13
A
GLU
11
-75.23
26.36
13
A
VAL
12
72.59
-58.27
13
A
HIS
13
90.41
-5.42
13
A
HIS
14
-124.77
-65.86
13
A
SER
26
-131.12
-34.50
14
A
HIS
6
-131.16
-58.69
14
A
SER
8
-170.53
24.69
14
A
VAL
12
-127.18
-56.68
14
A
HIS
13
89.41
-2.25
14
A
HIS
14
-100.90
-98.21
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
SOLUTION NMR STRUCTURE OF AMYLOID BETA[E16], RESIDUES 1-28, 14 STRUCTURES
1
Y
N
A
GLU
16
A
GLU
16
HELX_P
A
VAL
24
A
VAL
24
1
1
9
GLYCOPROTEIN
GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE
A4_HUMAN
UNP
1
1
P05067
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL
QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE
KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE
EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF
YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA
KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL
QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD
EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV
DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL
VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
672
699
1BJB
1
28
P05067
A
1
1
28
1
LYS
engineered mutation
GLU
16
1BJB
A
P05067
UNP
687
16
1
P 1